BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38130134)

  • 1. Supragastric lesser sac: an insidious site for surgical exploration during the debulking surgery in advanced ovarian cancer.
    Chen Y; Sun Z; Cai S; Hu Y; Jiang R; Xiang L; Zang R
    J Gynecol Oncol; 2024 May; 35(3):e25. PubMed ID: 38130134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metastatic Involvement of Lesser Sac in Advanced Epithelial Ovarian Cancer.
    Mukhopadhyay A; Bizzarri N; Bradbury M; Sinha S; Bhaumik J; Helm CW
    Int J Gynecol Cancer; 2018 Feb; 28(2):293-301. PubMed ID: 29324540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel classification of residual disease after interval debulking surgery for advanced-stage ovarian cancer to better distinguish oncologic outcome.
    Manning-Geist BL; Hicks-Courant K; Gockley AA; Clark RM; Del Carmen MG; Growdon WB; Horowitz NS; Berkowitz RS; Muto MG; Worley MJ
    Am J Obstet Gynecol; 2019 Oct; 221(4):326.e1-326.e7. PubMed ID: 31082382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer.
    Zivanovic O; Eisenhauer EL; Zhou Q; Iasonos A; Sabbatini P; Sonoda Y; Abu-Rustum NR; Barakat RR; Chi DS
    Gynecol Oncol; 2008 Feb; 108(2):287-92. PubMed ID: 17996927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of ablation and ultrasonic aspiration at primary debulking surgery in advanced stage ovarian, fallopian tube, and primary peritoneal cancer.
    Li S; Manning-Geist B; Gockley A; Ramos A; Sisodia RC; Del Carmen M; Growdon WB; Horowitz N; Berkowitz R; Worley M
    Int J Gynecol Cancer; 2020 Jul; 30(7):1052-1057. PubMed ID: 32487686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Target region resection in patients undergoing cytoreductive surgery for peritoneal metastases-is it necessary in absence of visible disease?
    Bhatt A; Yonemura Y; Mehta S; Benzerdjeb N; Kammar P; Parikh L; Shah MY; Shaikh S; Prabhu A; Mishra S; Sinukumar S; Kepenekian V; Bakrin N; Passot G; Glehen O
    Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):582-589. PubMed ID: 31757660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathologic distribution at the time of interval tumor reductive surgery informs personalized surgery for high-grade ovarian cancer.
    Bailey CD; Previs R; Fellman BM; Zaid T; Huang M; Brown A; Enbaya A; Balakrishnan N; Broaddus RR; Bodurka DC; Soliman P; Fleming ND; Nick A; Sood AK; Westin SN
    Int J Gynecol Cancer; 2021 Feb; 31(2):232-237. PubMed ID: 33122243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical characteristics and outcomes after bowel surgery and ostomy formation at the time of debulking surgery for advanced-stage epithelial ovarian carcinoma.
    Gockley AA; Fiascone S; Hicks Courant K; Pepin K; Del Carmen M; Clark RM; Goldberg J; Horowitz N; Berkowitz R; Worley M
    Int J Gynecol Cancer; 2019 Mar; 29(3):585-592. PubMed ID: 30833444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Success rate and safety of tumor debulking with diaphragmatic surgery for advanced epithelial ovarian cancer and peritoneal cancer.
    Saitou M; Iida Y; Komazaki H; Narui C; Matsuno K; Kawabata A; Ueda K; Tanabe H; Takakura S; Isonishi S; Sasaki H; Okamoto A
    Arch Gynecol Obstet; 2015 Mar; 291(3):641-6. PubMed ID: 25182215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns of diaphragm involvement in stage 3B/3C ovarian-tubal-peritoneal epithelial cancer patients and survival outcomes.
    Durmuş Y; İşçi Bostancı E; Duru Çöteli AS; Ünsal M; Kayıkçıoğlu F; Boran N
    Arch Gynecol Obstet; 2021 Jan; 303(1):241-248. PubMed ID: 32989507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary debulking surgery of the upper abdomen and the diaphragm, with a plasma device surgery system, for advanced ovarian cancer.
    Cordeiro Vidal G; Babin G; Querleu D; Guyon F
    Gynecol Oncol; 2017 Jan; 144(1):223-224. PubMed ID: 27836207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
    Yao SE; Tripcony L; Sanday K; Robertson J; Perrin L; Chetty N; Land R; Garrett A; Obermair A; Nascimento M; Tang A; Jagasia N; Singh P; Nicklin J
    Int J Gynecol Cancer; 2020 Dec; 30(12):1935-1942. PubMed ID: 33122245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of ultra-radical surgery in the management of patients with stage IIIC and IV epithelial ovarian, fallopian tube, and peritoneal cancer.
    Turnbull HL; Akrivos N; Wemyss-Holden S; Maiya B; Duncan TJ; Nieto JJ; Burbos N
    Arch Gynecol Obstet; 2017 Mar; 295(3):681-687. PubMed ID: 27995370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Greater-omentum lesion-score (GOLS) as a predictor of residual disease in different regions of the peritoneal cavity in patients undergoing interval cytoreductive surgery for advanced ovarian cancer and its potential clinical utility.
    Bhatt A; Kammar P; Rousset P; Sinukumar S; Mehta S; Parkih L; Goswami G; Shaikh S; Kepenkian V; Bakrin N; Devouassoux-Shisheboran M; Glehen O
    Eur J Surg Oncol; 2021 Nov; 47(11):2925-2932. PubMed ID: 34030922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of residual disease on overall survival in women with Federation of Gynecology and Obstetrics stage IIIB-IIIC vs stage IV epithelial ovarian cancer after primary surgery.
    Sørensen SM; Schnack TH; Høgdall C
    Acta Obstet Gynecol Scand; 2019 Jan; 98(1):34-43. PubMed ID: 30168853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimal residual disease at primary debulking surgery versus complete tumor resection at interval debulking surgery in advanced epithelial ovarian cancer: A survival analysis.
    Ghirardi V; Moruzzi MC; Bizzarri N; Vargiu V; D'Indinosante M; Garganese G; Pasciuto T; Loverro M; Scambia G; Fagotti A
    Gynecol Oncol; 2020 Apr; 157(1):209-213. PubMed ID: 31952843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Technical essentials and safety analysis of "rolling carpet" cytoreduction surgery in stage Ⅲc epithelial ovarian cancer].
    Liu H; Shi Y; Zhang GN; Yu J; Xu SQ; Wang DF; Fan Y; Song SQ; Zhou FZ
    Zhonghua Fu Chan Ke Za Zhi; 2020 Aug; 55(8):521-528. PubMed ID: 32854476
    [No Abstract]   [Full Text] [Related]  

  • 18. A multivariate analysis of the prognostic impact of tumor burden, surgical timing and complexity after complete cytoreduction for advanced ovarian cancer.
    Angeles MA; Rychlik A; Cabarrou B; Spagnolo E; Guyon F; Pérez-Benavente A; Gil-Moreno A; Siegrist J; Querleu D; Mery E; Gladieff L; Hernández A; Ferron G; Martinez A
    Gynecol Oncol; 2020 Sep; 158(3):614-621. PubMed ID: 32709536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel technique: Carbon dioxide gas-assisted total peritonectomy, diaphragm and intestinal meso stripping in open surgery for advanced ovarian cancer (Çukurova technique).
    Khatib G; Guzel AB; Gulec UK; Vardar MA
    Gynecol Oncol; 2017 Sep; 146(3):674-675. PubMed ID: 28720378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of primary cytoreduction on outcomes of patients with FIGO stage IIIC ovarian cancer stratified by the initial tumor burden in the upper abdomen cephalad to the greater omentum.
    Zivanovic O; Sima CS; Iasonos A; Hoskins WJ; Pingle PR; Leitao MM; Sonoda Y; Abu-Rustum NR; Barakat RR; Chi DS
    Gynecol Oncol; 2010 Mar; 116(3):351-7. PubMed ID: 20022092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.